#USA #Luxembourg #dBio #Nike #Bert Hoyt

Bert Hoyt Joins dBio as Board Advisor

Bert Hoyt, the former Vice President and General Manager of Nike, has taken on a pivotal role at Decentralized Biotechnology Intelligence Holding Group Inc. (dBio), a cutting-edge entity in the realm of sports and health technology. With over three decades of experience in the sports industry, Hoyt brings a wealth of knowledge and strategic insight as he joins dBio's Board of Advisors. His mission is to contribute to dBio's vision of advancing wearable health technology that merges athletic performance analysis with real-time health information.

A New Era in Sports Technology

dBio is at the forefront of innovation, offering advanced AIoT solutions designed to empower athletes and fitness enthusiasts. Their flagship technologies, gMOTCloud and StethoCloud, exemplify the company's commitment to enhancing sports performance and overall wellbeing. gMOTCloud is recognized as the original AI-powered kinesiology wearable, capturing intricate movement and gait metrics that help optimize athletic performance. StethoCloud, on the other hand, serves as a lightweight portable stethoscope that facilitates continuous heart and respiratory monitoring, enhanced by AI noise reduction capabilities. These devices are paired with cloud-based analytics, delivering personalized performance feedback and virtual training assistance.

Bert Hoyt's Impact on dBio

Hoyt’s illustrious career began in 1989 at Puma, where he climbed the ranks from product management to leading the brand globally. His transition to Nike in 1998 marked a significant turning point in his career. For 22 years, he served in various high-level roles, culminating in his position as VP and GM for Nike in Western Europe and EMEA. His leadership was instrumental in Nike's expansion to a market leader in these regions, with revenues soaring from $3 billion to over $10 billion.

Known for his deep understanding of consumer needs, Hoyt has a unique ability to mobilize teams around a clear consumer vision. His drive to provide athletes with premier products and brand experiences contributed to remarkable growth at Nike. After retiring from Nike in early 2021, he has assumed non-executive roles at several prestigious companies, showcasing his ongoing influence in the industry.

Hoyt's Commitment to Athlete Wellness

Hoyt expressed his enthusiasm about joining dBio, stating, "Throughout my personal and professional life, I have been dedicated to helping athletes enhance their performance and overall wellness. I believe dBio's innovations will set a transformative standard in sports performance, delivering precise data for improving and managing well-being for sports enthusiasts." His expertise will undoubtedly strengthen dBio’s mission as they persist in expanding globally and redefining personalized health technologies.

The Future of Health and Performance

With over 75 patents and proprietary technological advancements in AI modeling, hardware, software, and applications development, dBio is poised to provide a comprehensive solution for performance optimization and health management. This innovation is tailored not just for elite athletes but also extends to fitness enthusiasts, telemedicine applications, rehabilitation, and elder care solutions. dBio's collaborative partnerships with leaders in healthcare and academia reinforce the backbone of its advancements, positioning the company to lead the future of personalized health and performance technologies.

Summary

Bert Hoyt's addition to dBio emphasizes a strategic move towards combining sports technology with health analytics. His extensive background in brand management and consumer engagement brings a depth of insight that will drive dBio's mission forward. As they continue to innovate, the impact of Hoyt’s expertise may very well chart the future of sports performance optimization and personalized health management.